HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS/FDA Ephedra Strategy: A Risk Management Approach?

This article was originally published in The Tan Sheet

Executive Summary

HHS Secretary Tommy Thompson is urging manufacturers of ephedrine alkaloid supplements to include FDA's MedWatch toll-free number on labeling to better enable consumer reporting of adverse events

You may also be interested in...



Ephedra Product Liability Coverage Now Offered By Fewer Than 10 Insurers

Between five and 10 product liability companies have stopped offering coverage for ephedra alkaloid-containing products since June, when HHS Secretary Tommy Thompson issued a statement on ephedra's safety

Ephedra “Imminent Hazard” Declaration Sought By Sen. Durbin

Sen. Dick Durbin (D-Ill.) is pressing HHS Secretary Tommy Thompson to take immediate action against the sale of ephedra weight-loss dietary supplements by declaring the herbal ingredient an "imminent hazard.

Three-Step Supplement Safety Review Model Proposed by IoM

Outside review organizations could play a key role in preparing dietary supplement safety monographs as part of the Institute of Medicine's Proposed Framework for Evaluating the Safety of Dietary Supplements

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS131199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel